Study of RV521 in the Treatment of Adult Subjects Who Have Undergone HCT With an URTI With RSV

Summary

RV521 is to being developed to treat RSV infection and disease in susceptible individuals at high risk for complications. This is an international, multicenter, placebo-controlled study. Eligible subjects are adults with a documented symptomatic RSV infection who have undergone HCT transplantation and are moderately to severely immunocompromised. Qualified subjects will be randomized in a 1:1 ratio to receive RV521 or placebo, twice daily for 10 days.

Timeline

Start

2020-06-15

Primary completion

2023-06-30

Completion

2023-07-31

Drugs

Indications